1-4 of 4
Stephen P. Persaud
Close
Sort by
Journal Articles

Naked Antibody-Based Conditioning Targeting CD47 and CD117 Plus Janus Kinase Inhibition Enables Toxin-Free, Radiation-Free, and Chemotherapy-Free Fully Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio
Journal: Blood
Blood (2023) 142 (Supplement 1): 3421.
https://doi.org/10.1182/blood-2023-174989
Published: 2023
Journal Articles

Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning

Aditya R. Yelamali, Stephen P. Persaud, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 7359–7360.
https://doi.org/10.1182/blood-2022-162793
Published: 2022
Journal Articles

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 1570–1571.
https://doi.org/10.1182/blood-2022-157726
Published: 2022
Journal Articles

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud, MD PhD, Matthew L. Cooper, PhD, Julie K. Ritchey, Michael P. Rettig, PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3200.
https://doi.org/10.1182/blood-2019-123519
Published: 2019